Skip to content
Menu

Repligen Corporation RGEN

Full chart Compare
Set alert

Price alert · RGEN

All alert types
173.55 USD +11.37 (+7.01%)

As ofNov 18, 2026, 1:39 PM EST

163.01 Day range 174.44
102.87 52-week range 194.57
YTD
+5.91%
1 year
+13.39%
Market cap
11.09B
Revenue (ttm)
805.61M
Profit margin
-1.47%
EPS (ttm)
-0.21
Shares out
63.92M
Forward P/E
61.15
YTD return
+5.91%
1-year return
+13.39%
50-day average
177.05
200-day average
145.33
Volume
714.40K
Avg volume
1.19M
Open
163.03
Previous close
162.18
Day's range
163.01 – 174.44
52-week range
102.87 – 194.57
Beta
1.12
Analysts
Buy
Price target
203.21 (+17.1%)
Earnings date
Feb 23, 2027

5D +7.36 (+4.43%)

160165170175ThuFriMonTueWed173.40

Key statistics

Enterprise value
10.23B
PEG ratio
1.62
Price / sales
12.87
Price / book
4.40
Revenue growth
10.90%
Free cash flow
111.58M
Total cash
862.98M
Total debt
692.24M
Return on equity
-0.56%
Short % of float
11.06%

Fundamental scorecard

5 of 25 checks passed on RGEN’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 0 of 5
  • Growth 2 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
RGEN Revenue — quarterly 209.31M
RGEN Net income — quarterly -38.43M
RGEN EPS — quarterly -0.68

Earnings

RGEN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 23, 2027Dec 30, 20260.52———
Oct 27, 2026Sep 30, 20260.46280.53+0.07+14.52%
Jul 28, 2026Jun 30, 20260.4470.54+0.09+20.81%
May 5, 2026Mar 31, 20260.380.48+0.10+26.32%
Feb 24, 2026Dec 31, 20250.440.49+0.05+11.36%
Oct 28, 2025Sep 30, 20250.420.46+0.04+9.52%

Upgrades / downgrades

RGEN analyst upgrades and downgrades
DateFirmActionFromTo
Oct 28, 2026RBC CapitalmainOutperformOutperform
Oct 19, 2026Canaccord GenuitymainHoldHold
Oct 7, 2026BarclaysmainOverweightOverweight
Sep 9, 2026UBSmainBuyBuy
Jul 30, 2026Wells FargomainOverweightOverweight
Jul 29, 2026JP MorganmainOverweightOverweight

About Repligen Corporation

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States
Website
repligen.com

News

Your note

Sign in to keep a note on RGEN — it syncs with the Stock Master app.

Insider holders

RGEN insider holders
InsiderRelationLatest transactionDateShares held
BYLUND JAMESChief Operating OfficerStock Award(Grant)Mar 4, 202625,423
DAWES KAREN ADirectorStock Award(Grant)May 13, 202692,816
DOUGLASS BRIAN ROBBOfficerStock Award(Grant)Oct 5, 20268,685
GARLAND JASON K.Chief Financial OfficerSaleJul 15, 202618,829
HUGHES VIOLETTAOfficerStock Award(Grant)Mar 4, 20266,331
HUNT ANTHONY JOHNDirectorSaleNov 12, 202583,695

Institution ownership

RGEN institution ownership
Holder% heldSharesValueReported
FMR, LLC11.50%7,350,8731.19BSep 29, 2026
Blackrock Inc.8.96%5,726,731928.76MSep 29, 2026
United Capital Financial Advisors, LLC4.36%2,790,038452.49MSep 29, 2026
Vanguard Capital Management LLC3.82%2,442,741396.16MSep 29, 2026
Vanguard Portfolio Management LLC3.55%2,271,873368.45MSep 29, 2026
Invesco Ltd.3.34%2,134,062346.10MSep 29, 2026

Fund ownership

RGEN fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Mid-Cap ETF3.14%2,010,262326.02MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.66%1,702,844276.17MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund1.92%1,229,445199.39MJun 29, 2026
MFS Series Trust IV-MFS Mid Cap Growth Fund1.63%1,044,165169.34MAug 30, 2026
T. Rowe Price New Horizons Fund, Inc.1.51%963,028156.18MJun 29, 2026
Fidelity Contrafund1.33%851,928138.17MSep 29, 2026